Article Text

Download PDFPDF
440 Epidemiology and clinical profile of endometrial carcinosarcoma: a single institute experience
  1. Hend Mrad1,
  2. Yosr Zenzri1,
  3. Nadia Boujelbene2,
  4. Nesrine Kooli1,
  5. Najla Attia3,
  6. Montassar Ghalleb4,
  7. Azza Chabchoub4,
  8. Hajer Ben Mansour1,
  9. Amina Mokrani1,
  10. Mouna Ayadi1,
  11. Khedija Meddeb1,
  12. Nesrine Chraiet1,
  13. Henda Rais1,
  14. Feryel Letaief1 and
  15. Amel Mezlini1
  1. 1Medical oncology department, Salah Azaiez Institute, Tunis, Tunisia
  2. 2Pathology department, Salah Azaiez Institute, Tunis, Tunisia
  3. 3Radiotherapy department, Salah Azaiez Institute, Tunis, Tunisia
  4. 4Surgery department, Salah Azaiez Institute, Tunis, Tunisia


Introduction/Background Uterine carcinosarcomas are considered highly aggressive tumors associated with a poor prognosis. They associate carcinomatous and sarcomatous elements and arise from a single malignant clone. They represent rare gynecological tumors.

Methodology A monocentric retrospective study was conducted over a period of 7 years between 2017 and 2023 at the oncology department of Salah Azaiez Institute. Our study concerns women with uterine carcinosarcomas. All data regarding patients were obtained from the medical records.

Results Twenty-five patients were included. The median age was 64 years.The main symptom was postmenopausal metrorrhagia (96%). FIGO staging was respectively Stage I-II in 44% of the patients, Stage III in 32% and Stage IV in 24%. Surgery was performed in all patients. Four patients received neoadjuvant chemotherapy. 56% had complete resection, 24% had R1 resection and 20% R2 resection. 72% of patients had chemotherapy. Paclitaxel carboplatin was the most frequently used regimen. 52% of patients died mainly because of the progressive disease except for 3 cases due to complications after treatment with 1 anastomotic release post-surgery and 2 thromboembolic events. During follow-up, 12% of the patients relapsed after optimal treatment with mainly local and vaginal relapse. The majority of the patients alive (75%) had localized disease. The median survival was 22 months. The overall survival at 2 years was 46%.

Conclusion Uterine carcinosarcomas are aggressive tumors. Even with the association of surgery, chemotherapy and radiotherapy, the mortality rate is still high. It is important to optimize treatment to prevent the dissemination and improve the overall survival.

Disclosures We have no conflicts of interest to disclose. All authors declare that they have no conflicts of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.